

Literatura

- Alsanosi SMM, Skiffington C, Padmanabhan S. Pharmacokinetic pharmacogenomics. In: Padmanabhan S (Ed): Handbook of pharmacogenomics and stratified medicine. 341–364, Elsevier, Amsterdam 2014.
- Ansari A, Arenas M, Greenfield SM et al. Prospective evaluation of the pharmacogenetic of azathioprine in the treatment of inflammatory bowel disease. *Aliment Pharmacol Ther* 2008; 28: 973–983.
- Buzková H, Pechandová K, Danzig V et al. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. *Med Sci Monitor* 2012; 18: 512–517.
- Campbell TJ and Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. *Br J Clin Pharmacol* 2001; 52(Suppl 1): 21S–34S.
- Di Iulio, Fayet A, Arab-Alameddine M et al. Swiss HIV cohort study. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. *Pharmacogenet Genomics* 2009; 19: 300–309.
- Docherty KF and Padmanabhan S. Genomics and pharmacogenomics of lipid-lowering therapies. In: Padmanabhan S (Ed): Handbook of pharmacogenomics and stratified medicine. 715–746, Elsevier, Amsterdam 2014.
- Ehmann F, Caneva L, Papaluca M. European Medicines Agency initiatives and perspectives on pharmacogenomics. *Br J Clin Pharmacol* 2014; 77: 612–617.
- FDA. Pharmacogenomic Biomarkers in Drug Labeling. <http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics> (navštíveno 2. 9. 2015)
- Ghiculescu RA. Therapeutic drug monitoring: which drugs, why, when and how to do it. *Aust Prescr* 2008; 31: 42–44.

- Hagymási K, Müllner K, Herszényi L et al. Update on the pharmacogenomics of proton pump inhibitors. *Pharmacogenomics* 2011; 12: 873–888.
- Hanberger H, Edlund C, Furebring M et al. Rational use of aminoglycosides – review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). *Scand J Infect Dis* 2013; 45: 161–175.
- Hubáček JA, Adámková V, Zídková K a spol. Farmakogenetika léčby statiny. *Vnitř Lék* 2008; 54: 62–67.
- Johnston A, Holt DW. Therapeutic drug monitoring of immunosuppressant drugs. *Br J Clin Pharmacol* 1999; 47: 339–350.
- Kacířová I, Grundmann M. Terapeutické monitorování amikacinu a gentamicinu v rutinní klinické praxi. *Vnitř Lék* 2015; 61: 33–41.
- Karren P and Natalie A. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. *Nature Review Cancer* 2008; 8: 24–36.
- Kessler P. Farmakogenetika warfarinu. <http://www.thrombosis.cz/> (navštíveno 2. 9. 2015)
- Kollek R, Aken J, Feuerstein G et al. Pharmacogenetics, Adverse Drug Reactions and Public Health. *Community Genet* 2006; 9: 50–54.
- Krauss RM. What can the genome tell us about LDL cholesterol? *Lancet* 2008; 371: 450–452.
- Lesko LJ, Schmidt S. Clinical implementation of genetic testing in medicine: a US regulatory science perspective. *Br J Clin Pharmacol* 2014; 77: 606–611.
- Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. *Pharmacol Rev* 2011; 63: 437–459.
- Marcucci B, Cenci C, Cioni G et al. Antiplatelets in acute coronary syndrome: personal perspectives. *Expert Rev Cardiovascular Ther* 2012; 10: 1487–1496.
- McGraw J. CYP450 and ethnicity. In: Padmanabhan S (Ed): *Handbook of pharmacogenomics and stratified medicine*. 323–340, Elsevier, Amsterdam 2014.

- Mega LJ, Walker JR, Ruff CT et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet* 2015; 385: 2280–2287.
- Oh SJ, Hong KS, Lee KJ et al. Assessment of therapeutic drug monitoring of vancomycin in elderly patients according to new guidelines. *Ann Lab Med* 2014; 34: 1–6.
- Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. *Epilepsia* 2008; 49: 1239–1276.
- Perlík F. Vliv jaterní cirhózy na farmakokinetiku a farmakodynamiku léčiv. *Vnitř Lék* 2013; 59: 584–586.
- Perlík F. Etické aspekty farmakogenetiky, 115–122. In: Ptáček R, Bartůněk P (Ed): *Etické problémy medicíny na prahu 21. století*. Grada Publishing a.s., Praha 2014.
- Perlík F. Podávání léků u starších nemocných se sníženou renální funkcí. In: Teplan V a spol.: *Nefrologie vyššího věku*. 209–219, Mladá fronta a.s., Praha 2015.
- Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med* 2013; 369: 2294–3303.
- Price MJ, Berger PB, Teirstein PS et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011; 305: 1097–1105.
- Prokeš M, Suchopár J. Prodloužení intervalu QT způsobené léky. *Med praxi* 2014; 11: 34–39.
- Scott SA, Sangkuhl K, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. *Clin Pharmacol Ther* 2013; 94: 317–323.
- Slanař O, Draždáková M, Babiárová K et al. Genotypizace cytochromu P450 2D6 a 2C19. *Čas Lék čes* 2007; 146: 708–711.

- Slanař O, Chalupná P, Novotný A et al. Fatal myelotoxicity after azathioprine treatment. *Nucleosides, Nucleotides and Nucleic Acids* 2008; 27: 661–665.
- Thummel KE, Shen DD, Isoherranen N et al. Design and optimization of dosage regimens: Pharmacokinetic data. In: Brunton LL (Ed): Goodman and Gilman's *The pharmacological basis of therapeutics*, 11/E. 1787–1888, McGraw-Hill, New York 2006.
- Trenk D and Hochholzer W. Genetics of platelet inhibitor treatment. *Br J Clin Pharmacol* 2014; 77: 642–653.
- Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. *Eur J Clin Pharmacol* 2008; 64: 1147–1161.
- Verhoef TI, Redekop WK, Daly AK et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. *Br J Clin Pharmacol* 2014; 77: 626–641.
- Viklický O. Imunosuprese po transplantaci ledviny. *Klin Farmakol Farm* 2010; 24: 98–102.
- Wilkinson GR. Drug metabolism and variability among patients in drug response. *N Engl J Med* 2005; 352: 2211–2221.
- Walker L, Yip V, Pirmohamed M. Adverse drug reactions. In: Padmanabhan S (Ed): *Handbook of pharmacogenomics and stratified medicine*. 405–435, Elsevier, Amsterdam 2014.
- Yasuda SU, Zhang L, Huang SM. The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies. *Clin Pharmacol Ther* 2008; 84: 417–423.
- Yip VL, Alfveric A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. *Clin Rev Allergy Immunol* 2015; 48: 165–175.
- Zima T, Teplan V, Tesař V et al. Doporučení České nefrologické společnosti a České společnosti klinické biochemie ČLS JEP k vyšetřování glomerulární filtrace, 2013; <http://www.nefrol.cz>.